SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors
Authors:
- R.A. WernerRWR.A. Werner
- Christina BluemelCBChristina Bluemel
- M. LassmannMLM. Lassmann
- T. KudlichTKT. Kudlich
- T. HiguchiTHT. Higuchi
- Egesta LopciEgesta Lopci
- M. Allen-AuerbachMAM. Allen-Auerbach
- Patrick M. CollettiPCPatrick M. Colletti
- Domenico RubelloDomenico Rubello
- M.C. ZatelliMZM.C. Zatelli
- Ken HerrmannKHKen Herrmann
- 1 May 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (5) , e271-e277
Abstract
The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECT and PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring. Moreover, we will discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally, we will discuss which new concepts will most likely influence the theranostic treatment approach in NETs in the future.Keywords
This publication has 56 references indexed in Scilit:
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical studyEJNMMI Research, 2012
- Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PETJournal of Nuclear Medicine, 2010
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumoursBritish Journal of Cancer, 2010
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnalogsNeuroendocrinology, 2009
- A comprehensive overview of radioguided surgery using gamma detection probe technologyWorld Journal of Surgical Oncology, 2009
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor TargetingClinical Cancer Research, 2008
- Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitroNuclear Medicine and Biology, 2006